![]() ![]() Many people got to see that Merck’s drug has a serious issue of mutagenicity. The article got over 35K hits at the time of writing, and was the top contributor article for 2 days running. Other antivirals like Pfizer’s oral antiviral are designing the same sort of clinical trial of exclusion. Many failed to read the fine print that the drug was for unvaccinated people which happens to be a shrinking demographic and people with at least one underlying condition. It’s not for the masses, but that is precisely what investors assumed when the news broke. The key points that were uncovered is that Molnupiravir is for a very limited population of patients. ![]() Likewise vaccine stocks like Moderna (NASDAQ: MRNA), Pfizer (NYSE: PFE), BioNTech (NASDAQ: BNTX), Johnson & Johnson (NYSE: JNJ), Vir Technology (NYSE: VIR), and Novamax (NASDAQ:NVAX) are expected to rebound. Merck (NYSE: MRK) is expected to be under pressure Monday as the euphoria starts to wear off and reporters start to dig and ask questions. ![]() It also became clearer that both leronlimab and Tollovir might really have a better solution than a vaccine for the entire spectrum of disease. Over the weekend it’s become clear that Molnupiravir is no savior let alone a magic bullet and the road to approval is still a rocky one given the campaign to continue vaccinations. The sell off in both CYDY and TOMDF was probably attributable to the investor rationalization that now a magic bullet exists to treat COVID-19 early it was therefore time to trim Covid therapeutics because they won’t be necessary. In the article it broke down the mechanism of action of Molnupiravir which was the top headline on Friday which almost single handedly moved the market higher. in a recent article there were a lot of comments about leronlimab and Tollovir. (OTCMKTS: CYDY) might be looking at a pretty good week ahead of them. Brooklyn fans can rest easy knowing that Clowney will be working hard from his first day as a Net.Todos Medical (OTCMKTS: TOMDF) and CytoDyn Inc. It sounds like Clowney is invested in doing what he can to help the Nets win games next season and beyond. “I want to be in conversations for Defensive Player of the Year awards,” Clowney said. Clowney has loftier goals than that, however. Clowney, from Roebuck, SC, which is about 30 miles from where Nets starting center Nic Claxton grew up in Greenville, SC, has a lot that he wants to accomplish and seems like he has the confidence in himself to make it happen.Ĭlowney has some developing to do as he needs to fill out his body, 210 pounds while being 6-foot-10, but he can provide versatility on the defensive end as well as being able to score at the rim when needed. Obviously, I want to get better and perfect my game in every part possible,” Clowney continued. “I never really think about me individually. “Two to three years from now, that’s hard,” Clowney said. While Clowney had said in the beginning of his press conference that he believes that he can bring a lot to Brooklyn right away, it was interesting to ask where he sees himself as a player 2-3 years from now. NEW YORK - Former Alabama big man Noah Clowney became a member of the Brooklyn Nets on Thursday and afterwards, he spoke to the media to share his thoughts and goals. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |